All News


All series


All All News

FDA Approves New Formulation of the PSMA PET Agent Pylarify

Designed to enhance product stability at higher radioactive concentrations, the PSMA PET imaging agent Pylarify TruVu (piflufolastat F 18) may facilitate enhanced supply flexibility and access for men with suspected recurrence or metastasis of prostate cancer.